Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JEV-PLLAV vaccine
- Development stage
- Preclinical
- Lead developer
- ViroVet
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Needle-free (jet-injector), In Vivo Injection Of Naked Dna
01
Overview
JEV-PLLAV vaccine is a veterinary vaccine candidate developed by ViroVet for the prevention of Japanese encephalitis (JE) in swine. The vaccine utilizes ViroVet's proprietary Plasmid-Launched Live Attenuated Virus (PLLAV) technology, which involves the administration of a DNA plasmid that encodes the entire genome of a live attenuated virus. Once inside the host cells, the plasmid initiates the replication of the attenuated virus, effectively 'launching' a live-virus infection that triggers a robust and comprehensive immune response. This approach combines the manufacturing stability and safety profile of DNA vaccines with the high immunogenicity of live attenuated vaccines. In swine, which serve as a major amplifying reservoir for the Japanese encephalitis virus, the vaccine has demonstrated strong protective efficacy in preclinical studies reported as of late 2021.
- Other names
- PLLAV vaccine (JEV)Japanese encephalitis vaccine (ViroVet)JEV-PLLAV
Beyond the preview
Go deeper on JEV-PLLAV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JEV-PLLAV vaccine.